secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001564590-21-042675
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q2 revenue $153.6M (+790% YoY); acquires CSI Labs, invests in Helio Health and FF Gene Biotech
--------------------------------------------------------------------------------

- Q2 revenue $153.6M (+790% YoY); ~1.6M billable tests (9x YoY); gross margin improved ~21pp YoY.
- GAAP net income $79.8M ($2.59 EPS); non-GAAP net income $78.7M ($2.55 EPS); adjusted EBITDA $105.0M.
- Core (NGS) revenue grew 296% YoY to $25.7M.
- Acquisition of CSI Laboratories (cancer diagnostics) and commercial agreement with Helio Health via strategic investment.
- Incremental controlling investment in Chinese JV FF Gene Biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000156459021042675/0001564590-21-042675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000156459021042675/flgt-8k_20210809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-042675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer